Our results suggest that although no chemical inhibitors have been designed with the specific goal of targeting APLP2, existing beta-secretase inhibitors that have been made to target APP for the treatment of Alzheimer's disease may potentially be repurposed to target APLP2. This evidence concerns the gene APP and Alzheimer disease.